Combining blood biomarkers and the German version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID‐G) for diagnosing cognitive decline in Down syndrome
Open Access
- 20 March 2026
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71296
Abstract
INTRODUCTION: Individuals with Down syndrome (DS) are at risk for Alzheimer's disease (AD). However, diagnosis remains challenging due to variability of intellectual ability and symptom presentation. To investigate whether serum AD biomarkers enhance accuracy of the German version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID‐G), we combined test scores with neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels. METHODS: Seventy‐eight DS individuals (49% female) completed the DSQIID‐G; previous cohort data were added for a pooled sample ( n = 164, 47% female). Serum NfL and GFAP were assessed using the automated microfluid Ella system. RESULTS: Combining the DSQIID‐G with NfL or GFAP resulted in improved accuracy in every diagnostic subgroup. The Youden index in the pooled samples yielded a cut‐off score at 6.5. DISCUSSION: The DSQIID‐G is a robust screening tool and its combination with AD blood biomarkers aids earlier identification of individuals requiring further diagnostics for DS‐associated AD.Keywords
This publication has 29 references indexed in Scilit:
- Imaging and plasma biomarkers for pathological accumulation in Down syndromeBrain, 2025
- Age-Specific Control and Alzheimer Disease Reference Curves and z -Scores for Glial Fibrillary Acidic Protein in BloodClinical Chemistry, 2025
- Blood‐based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta‐analysisAlzheimer's & Dementia, 2025
- AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndromeAlzheimer's & Dementia, 2023
- Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort studyEBioMedicine, 2023
- Role of tau deposition in early cognitive decline in Down syndromeAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022
- The French translation of the dementia screening questionnaire for individuals with intellectual disabilities is a sensitive tool for screening for dementia in people with Down SyndromeResearch in Developmental Disabilities, 2021
- Evaluation of the National Task Group‐Early Detection Screen for Dementia: Sensitivity to ‘mild cognitive impairment’ in adults with Down syndromeJournal of Applied Research in Intellectual Disabilities, 2020
- Amnestic and non‐amnestic symptoms of dementia: An international study of Alzheimer's disease in people with Down's syndromeInternational Journal of Geriatric Psychiatry, 2020
- Dementia diagnostic criteria in Down syndromeInternational Journal of Geriatric Psychiatry, 2014